Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients

Journal of Clinical Psychiatry

Volumn 66, Issue 2, 2005, Pages 174-182

  Baethge, Christopher ^a,e   Baldessarini, Ross J ^a   Mathiske Schmidt, Kirsten ^b   Hennen, John ^a   Berghöfer, Anne ^b   Müller Oerlinghausen, Bruno ^c   Bschor, Tom ^d   Adli, Mazda ^b   Bauer, Michael ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d Jewish Hospital of Berlin   (Germany)

^e MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; LITHIUM; PSYCHOTROPIC AGENT;

ADULT; APPETITE DISORDER; ARTICLE; BIPOLAR DISORDER; BODY WEIGHT DISORDER; CLINICAL ARTICLE; DIARRHEA; DROWSINESS; FEMALE; GASTROINTESTINAL SYMPTOM; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; RECURRENCE RISK; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TREMOR;

EID: 14644442268     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0204     Document Type: Article

References (46)

1. Kraepelin E. Manic-Depressive Insanity and Paranoia. Edinburgh, UK: E&S Livingstone; 1921
2. Gitlin MJ, Swendson J, Heller TL, et al. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635-1640
3. Müller-Oerlinghausen B. Does effective lithium prophylaxis result in a symptom-free state of manic-depressive illness? some thoughts on the fine-tuning of mood stabilization. Compr Psychiatry 2000;41 (suppl 1):26-31
4. Judd LL, Akiskal HS, Schettler PJ. The long-term natural history of a weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;39:530-537
5. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-690
6. Joffe RT, MacQueen GM, Marriott M, et al. A prospective, longitudinal study of percentage of time spent ill in patients with bipolar I or bipolar II disorders. Bipolar Disord 2004;6:62-66
7. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman JG, Limbird LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill Press; 2005. In press
8. Fenn HH, Robinson D, Luby V, et al. Trends in pharmacotherapy of schizoaffective and bipolar affective disorders: 5-year naturalistic study. Am J Psychiatry 1996;153:711-713
9. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099-2107
10. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000;61:9-15
11. Kupfer DJ, Frank E, Grochocinski VJ, et al. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120-125
12. al-Ghamdy YS, Qureshi NA, Abdelghadir MH, et al. Psychotropic drugs prescriptions in Al-Qassim region, Saudi Arabia. East Mediterr Health J 1999;5:27-34
13. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment: patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14:33-40
14. Lloyd AJ, Harrison CL, Ferrier IN, et al. The pharmacological treatment of bipolar disorder: practice is improving but could still be better. J Psychopharmacol (Oxf) 2003;17:230-233
15. Freeman MP, Stoll AL. Mood stabilizer combinations: review of safety and efficacy. Am J Psychiatry 1998;155:12-21
16. Ghaemi SN. Polypharmacy of bipolar disorder. In: Ghaemi SN, ed. Polypharmacy in Psychiatry. New York, NY: Marcel Dekker; 2002: 35-77
17. Goodwin FK. Rationale for using lithium in combination with other mood stabilizers in the management of bipolar disorder. J Clin Psychiatry 2003;64(suppl 5):18-24
18. Zarate CA Jr, Quiroz JA. Combination treatment in bipolar disorder: review of controlled trials. Bipolar Disord 2003;5:217-225
19. Inoue K, Arima S, Tanaka K, et al. A lithium and carbamazepine combination in the treatment of bipolar disorder: preliminary report. Folia Psychiatr Neurol Jpn 1981;35:465-475
20. Pies R. Combining lithium and anticonvulsants in bipolar disorder: a review. Ann Clin Psychiatry 2002;14:223-232
21. Solomon DA, Keitner GI, Ryan CE, et al. Lithium plus valproate as maintenance polypharmacy for patients with bipolar disorder: a review. J Clin Psychopharmacol 1998:18:38-49
22. Centorrino F, Albert MJ, Berry JM, et al. Oxcarbazepine: clinical experience with hospitalized psychiatric patients. Bipolar Disord 2003;5:370-374
23. Ghaemi SN, Berv DA, Klugman J, et al. Oxcarbazepine treatment of bipolar disorder. J Clin Psychiatry 2003;64:943-945
24. Evins AE. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J Clin Psychiatry 2003;64(suppl 8):9-14
25. Nolen WA. Carbamazepine, a possible adjunct or alternative to lithium in bipolar disorder. Acta Psychiatr Scand 1983;67:218-225
26. Fawcett J, Kravitz HM. The long-term management of bipolar disorders with lithium, carbamazepine, and antidepressants. J Clin Psychiatry 1985;46:58-60
27. Shukla S, Cook BL, Miller MG. Lithium-carbamazepine vs lithium-neuroleptic prophylaxis in bipolar illness. J Affect Disord 1985;9:219-222
28. Lovett L, Watkins SE, Shaw DM. The use of alternative drug therapy in nine patients with recurrent affective disorder resistant to conventional prophylaxis. Biol Psychiatry 1986;21:1344-1347
29. Cabrera J, Albrecht J, Müller-Oerlinghausen B. Kombinierte rezidivprophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin. [Combined preventive treatment of recurrent manic-depressive disease with lithium and carbamazepine or oxcarbazepine.] Nervenarzt 1987;58:245-249
30. Post RM, Leverich GL, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990;10:318-327
31. Strömgren LS. The combination of lithium and carbamazepine in treatment and prevention of manic-depressive disorder: review and case report. Compr Psychiatry 1990;31:261-265
32. Di Costanzo E, Schifano F. Lithium alone or in combination with carbamazepine for the treatment of rapid cycling bipolar disorder. Acta Psychiatr Scand 1991;83:456-459
33. Kishimoto A. The treatment of affective disorder with carbamazepine: prophylactic synergism of lithium and carbamazepine combination. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:483-193
34. Fritze J, Beneke M, Lanczik M, et al. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders. Pharmacopsychiatry 1994;27:181-185
35. Peselow ED, Fieve RR, Difilia C, et al. Lithium prophylaxis of bipolar illness: value of combination treatment. Br J Psychiatry 1994;164: 208-214
36. Bocchetta A, Chillotti C, Severino G, et al. Carbamazepine augmentation in lithium-refractory bipolar patients: a prospective study on long-term prophylactic effectiveness. J Clin Psychopharmacol 1997;17:92-96
37. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. S Clin Psychiatry 1997;58:470-478
38. Berghöfer A, Kossmann B, Müller-Oerlinghausen B. Course of illness and pattern of recurrences in patients with affective disorders during long-term lithium prophylaxis: a retrospective analysis over 15 years. Acta Psychiatr Scand 1996;93:349-354
39. Baethge C, Smolka MN, Gruschka P, et al. Does prophylaxis-delay in bipolar disorder influence outcome? results from a long-term study of 147 patients. Acta Psychiatr Scand 2003;107:260-267
40. Grof P, Aida M, Grof E, et al. The challenge of predicting response to stabilising lithium treatment: the importance of patient selection. Br J Psychiatry 1993;163(suppl 21):16-19
41. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorders: results of the MAP study. Neuropsychobiology 2000;42(suppl 1):2-10
42. Hartong EGTM, Moleman P, Hoogduin CAL, et al, and the LitCar Group. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003;64:144-151
43. Chaudhry RP, Waters BGH. Lithium and carbamazepine interaction: possible neurotoxicity. J Clin Psychiatry 1983;44:30-31
44. Shukla S, Godwin CD, Long LEB, et al. Lithium-carbamazepine neurotoxicity and risk factors. Am J Psychiatry 1984;141:1604-1606
45. Grof P. Selecting effective long-term treatment for bipolar patients: monotherapy and combinations. J Clin Psychiatry 2003;64(suppl 5): 53-61
46. Tohen M, Chengappa KMR, Suppes T, et al. Relapse prevention in bipolar I disorder: 18 month comparison of olanzapine plus mood stabilizer vs mood stabilizer alone. Br J Psychiatry 2004;184:337-345